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Abstract
Posttransplant lymphoproliferative disorders (PTLDs), 50%‐80% of which are
strongly associated with Epstein‐Barr virus (EBV), carry a high morbidity and mortality. Most clinical/epidemiological/tumor characteristics do not consistently associate with worse patient survival, so our aim was to identify if other viral genomic
characteristics associated better with survival. We extracted DNA from stored paraffin‐embedded PTLD tissues at our center, identified viral sequences by metagenomic
shotgun sequencing (MSS), and analyzed the data in relation to clinical outcomes.
Our study population comprised 69 PTLD tissue samples collected between 1991
and 2015 from 60 subjects. Nucleotide sequences from at least one virus were detected by MSS in 86% (59/69) of the tissues (EBV in 61%, anelloviruses 52%, gammapapillomaviruses 14%, CMV 7%, and HSV in 3%). No viruses were present in
higher proportion in EBV‐negative PTLD (compared to EBV‐positive PTLD). In
univariable analysis, death within 5 years of PTLD diagnosis was associated with
anellovirus (P = 0.037) and gammapapillomavirus (P = 0.036) detection by MSS,
higher tissue qPCR levels of the predominant human anellovirus species torque teno
virus (TTV; P = 0.016), T cell type PTLD, liver, brain or bone marrow location. In
multivariable analyses, T cell PTLD (P = 0.006) and TTV PCR level (P = 0.012)
remained significant. In EBV‐positive PTLD, EBNA‐LP, EBNA1 and EBNA3C had
significantly higher levels of nonsynonymous gene variants compared to the other
EBV genes. Multiple viruses are detectable in PTLD tissues by MSS. Anellovirus
positivity, not EBV positivity,was associated with worse patient survival in our series. Confirmation and extension of this work in larger multicenter studies is
desirable.
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BACKGROU N D

Posttransplant lymphoproliferative disorders (PTLDs), an abnormal proliferation of lymphoid cells under posttransplant
immunosuppression, are a major malignant complication of
organ and tissue transplant.1-4 PTLDs have a high morbidity and
5‐year mortality that exceeds 50%.3 About 50%‐80% of PTLD
cases are strongly related to the oncogenic Epstein‐Barr virus
(EBV).5 Cytomegalovirus seromismatch has been associated
in some studies6,7 but not consistently. It is not known whether
other viruses are also associated with PTLD. While recent mortality rates have decreased with general medical advances and
newer therapies,8,9 mortality remains high10 and graft failure is a
significant complication of interventions.11 Though many prognostic indices have been used to predict survival after PTLD,
mortality after PTLD is not fully explained by these indices.12-14
These indices vary considerably in their component prognostic factors; they do not consistently include the same clinical,
viral, epidemiologic or tumor characteristics. Therefore, host
responses to EBV and the degree of overall immunosuppression
have been studied as possible contributors to prognosis and outcome, but still do not fully explain the outcomes.15-17
Our aim was to determine whether there were DNA viruses associated with EBV‐negative PTLD or PTLD outcomes using metagenomic shotgun sequencing (MSS) of
archived formalin‐fixed paraffin‐embedded (FFPE) tissue
samples from PTLD patients. MSS is an approach that assesses genomic material from host and microbes within a
sample, allowing for the culture‐independent detection of
microbes without a priori knowledge of which viral groups
are present with a sample. Like genome‐wide association
tools, MSS is a powerful tool for studying viruses in clinical
samples because it allows evaluation of a comprehensive set
of viruses simultaneously. In addition, MSS can provide genomic data that can be used to assess features or variants that
may associate with virulence or pathogenicity. Our approach
included the use of ViroCap™, a targeted sequence capture
method that we developed recently to enhance detection of
viral sequences by MSS.18 This improved methodology allows us to thoroughly characterize the viruses associated
with PTLD, and eventually study how EBV genome variants
contribute to more severe presentations or worse outcomes.
We can also study which viruses, if any, are associated with
EBV‐negative PTLD. We undertook this genomic analysis
because these newer technologies could lead to new information and insights not found with other methods.

2

|

METHODS

This study was approved the Human Subjects Research
Protection Office at Washington University School of
Medicine.
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2.1

|

Tissue sample identification

|

DNA extraction and MSS

|

EBV variant analysis

We first identified through a search of our electronic medical
records that all tissue blocks from PTLD cases available in
the tissue archives of the Washington University School of
Medicine Pathology Department. Tissue specimens of sufficient quantity (as evaluated by hematopathologist MBR)
were selected for nucleic acid extraction. We also identified 8 EBV‐negative control tissues (abdominal lymph
nodes from cases of diverticulitis, prolapse, appendicitis or
gunshot wound) and four positive EBV‐positive control tissues that were either Hodgkin lymphoma or diffuse large B
cell lymphoma (DLBCL) from immunocompetent patients
in a nontransplant setting. Pathological and clinical covariates extracted for the PTLD specimens are described in
Supplementary Methods.

2.2

DNA extraction methods are described in Supplementary
Methods. We generated dual‐indexed sequencing libraries from the DNA using the KAPA Low Throughput
Library Construction Kit (KAPA Biosystems, Wilmington,
Massachusetts). We pooled libraries and mixed them with the
ViroCap™ targeted sequence capture probes (synthesized by
Nimblegen®), which target and enrich genomes from a comprehensive set of vertebrate viruses to enhance sensitivity.
Targeted sequence capture was carried out according to the
manufacturer's instructions. We sequenced the enriched viral
nucleic acids using the Illumina HiSeq 2000/2500 platform.
We analyzed sequences using a pipeline adapted from the
method previously described by us19 except that Burroughs
Wheeler Alignment tool BWA MEM was used for the nucleotide sequence alignments.20 To avoid false positives resulting from index swapping during capture,21-23 in which the
library‐specific indexes are transferred between libraries at a
low frequency, we subtracted 0.1% of the total viral reads for
each virus within a pool from each sample. This threshold
was based on published studies21-23 and our experience with
capture of dual‐indexed sequencing libraries.18 Samples with
viral signal above or below that threshold were considered
positive or negative, respectively, as a categorical variable.
Sequences were manually reviewed to verify classification of
herpesvirus and polyomavirus sequences.

2.3

For samples that were positive for EBV sequences, sequences were aligned to canonical EBV‐1 and EBV‐2 reference genomes (NCBI Reference Sequence: NC_007605.1
and NC_009334.1). The depth and breadth of coverage
were calculated using RefCov (http://gmt.genome.wustl.
edu/packages/refcov/), and alignments were reviewed
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to determine EBV type. Samples in which >70% of the
EBV‐1 genome represented in the sequencing data were
included in subsequent comparative analysis. Variants
compared to the reference EBV‐1 genome were identified
using Varscan, a platform‐independent software tool developed at the McDonnell Genome Institute at Washington
University to detect variants in genomic data.24 For variant analysis, nucleotide positions with <10× read depth
were classified as unevaluable and excluded. Variants and
coverage were manually reviewed using Tablet, a high‐performance graphical viewer for metagenomic sequence assemblies and alignments.25

2.4

|

2.4.1

Polymerase chain reaction

|

Statistical analyses

1015

Tissue specimens were tested by quantitative PCR assays
for EBV and the predominant anellovirus species in humans, torque teno virus (TTV), alpha subtype. Details of the
PCR assays are described in the Supplementary Methods.

2.4.2

Details of the statistical analyses are in the Supplementary
Methods.

3

Data submission

3.1

Submission of microbial sequencing data to the public
Sequence Read Archive is in progress at the time of submission, and BioProject and SRS identifiers will be provided
prior to publication.
TABLE 1

|

|

|

RESULTS

|

Subjects and samples

We identified 163 records in the Department of Pathology
tissue archives, of which 69 specimens from 60 subjects
from the period 1991‐2015 were adequate for analysis

Study subject (n = 60) and sample (n = 69) characteristics
Polymorphic

Patients

16

DLBCL

T cell

Classic Hodgkin

3

5

12.98 ± 17.16

27.78 ± 22.90

15.23 ± 25.78

40.66 ± 23.43

Age at transplant under
21 years

14 (87.5)

16 (53.33)

2 (66.67)

1 (20)

2 (33.33)

35

Male

11 (68.75)

16 (53.33)

2 (66.67)

3 (60)

4 (66.67)

36

Subject death

6 (37.5)

14 (46.67)

1 (33.33)

4 (80)

1 (16.67)

26

Death‐censored graft failurea

2 (12.5)

2 (6.67)

0 (0)

0 (0)

1 (16.67)

5

6

60

4 (66.67)

15

Organ transplant type
Kidney

16

30

3

5

3 (18.75)

5 (16.67)

0 (0)

3 (60)

5 (16.67)

0 (0)

0 (0)

6

Total

Age at transplant
(years ± SD)

a

30

Burkitt/Plasma Cell

60

28.57 ± 17.35

Liver

0 (0)

Heart

2 (12.5)

6 (20)

1 (33.33)

0 (0)

Lung

9 (56.25)

11 (36.67)

2 (66.67)

2 (40)

1 (16.67)

25

1 (16.67)

2

Bone marrow

1 (6.25)

0 (0)

0 (0)

0 (0)

Multiple

1 (6.25)

3 (10)

0 (0)

0 (0)

97 (85, 145)

132 (57, 164)

5

6

Median months from
transplant to PTLD (Q1, Q3)
Sample location

37 (6, 69)

28.5 (7, 127)

0 (0)

5

0 (0)

9

0 (0)

4

116 (102, 199)

18

34

7 (38.89)

4 (11.76)

1 (20)

1 (16.67)

6 (100)

19

GI tract

1 (5.56)

14 (41.18)

5 (100)

1 (16.67)

0 (0)

21

Liver

1 (5.56)

5 (14.71)

0 (0)

0 (0)

0 (0)

6

CNS

0 (0)

2 (5.88)

0 (0)

1 (16.67)

0 (0)

3

Disseminated

1 (5.56)

3 (8.82)

1 (20)

3 (50)

Bone Marrow

1 (5.56)

0 (0)

0 (0)

2 (33.33)

Lymph node

Lung

2 (11.11)

6 (17.65)

0 (0)

0 (0)

Other

7 (38.89)

6 (17.65)

0 (0)

3 (50)

Numbers in parentheses indicate percentages. DLBCL, diffuse large B cell lymphoma.
a
Subject death and death‐censored graft failure were assessed within 5 years of the diagnosis of PTLD.

6

1 (16.67)

69

9

0 (0)

3

0 (0)

8

0 (14.29)

16

1016
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according to the described criteria. The male: female ratio
was 36:24. The median age of the subjects was 15.1 years
(range 0.1 to 67.9 years; mean 22.7, <21 years at time of
transplant = 35/60). Subjects with polymorphic PTLD were
younger at transplant (median age 13.0 years) than other
groups, while the subjects with T cell PTLD were older
at transplant (median age 40.7 years) than other groups
(Table 1).
The transplanted organ was distributed across all the
major types, lung being the most common (Table 1).
PTLD was located in diverse locations, lymph node and GI
tract being the most common. Applying the World Health
Organization (WHO) classification of PTLD,26,27 our 69 tissue cases were mostly monomorphic B cell type in 39 (of
which 34 were DLBCL and five were other types). For the 8
subjects who had more than 1 PTLD occurrence (one subject
had two recurrences), the PTLD WHO type was the same in
each occurrence, except in one subject, who had a Hodgkin
type PTLD initially and a DLBCL type in the recurrence
3 years later.
Death‐censored graft failure occurred in 8/60 (six in
patients who later died) at a median time of 3.2 years after
PTLD diagnosis (IQR 0.6‐7.2 years). Of the eight graft failures, five grafts failed within 5 years of the PTLD diagnosis.
Thirty‐two patients had died at the time the samples were
analyzed, at a median time of 3.5 years after PTLD diagnosis
(IQR 0.7‐8.1 years, range 0–18.8 years). Of the 32 deaths, 26
died within 5 years of the PTLD diagnosis.

3.2 | Detection of viral nucleotide sequences
by MSS
Nucleotide sequences from at least one virus were detected
by MSS in 86% (59/69) of the sequenced PTLD samples.
Figure 1 depicts the viral sequences detected. EBV was
detected in 61% (42/69) of the PTLD samples, and it was
also detected in all of the 4 EBV positive control samples
but not in any of the eight negative controls. Of the single‐
stranded DNA viruses, anelloviruses were detected in 52% of
the PTLD samples. Positivity by MSS for a viral genus was
handled as a categorical yes/no variable in further analyses.
When correlating with WHO classification, all six Hodgkin
lymphoma cases were EBV sequencing positive and 5/6 were
roseolovirus positive while all six T cell PTLDs were EBV
sequencing negative (see Figure 1 for breakdown according
to WHO PTLD type and see Figure S1). Anellovirus positivity by MSS did not associate with PTLD WHO type (Figure
S1).

3.3

|

EBV genome variants

We had >70% of the EBV genome length represented in
the sequence data from samples from 37 unique PTLD

DHARNIDHARKA et al.

F I G U R E 1 DNA viruses detected in stored PTLD tissues,
stratified by WHO type. Each row represents a different sequenced
sample. Viruses are noted in columns. A dark bar indicates the virus
was detected in that sample, and gray background indicates the virus
was not detected

patients, 33 EBV‐1 and 4 EBV‐2. The 33 EBV‐1 samples were used for subsequent comparative analysis. We
chose to focus on nine specific EBV genes that are most
associated with oncogenesis or with viral latency profiles.2 We determined the nucleotide variants in each of
these nine genes and classified variants as synonymous
(no change in the predicted amino acid coding) vs nonsynonymous (predicted change in the amino acid coding,
and therefore more likely to be pathogenic). As shown in
Table 2, the genes EBNA3C, EBNA‐LP, and LMP1 had
a greater ratio of nonsynonymous changes to synonymous changes, suggesting a greater chance of pathogenic
variants within these genes. Logistic regression analyses
showed that the genes with the highest percent nonsynonymous changes were EBNA‐LP (significantly higher
than all other genes), and EBNA1 and EBNA3C (significantly lower than EBNA‐LP but significantly higher than
all other genes; Figure 2).

3.4 | MSS viral genome detection in EBV‐
negative PTLD
The distribution of the different viruses in the EBV‐negative
PTLD tissues is shown in Figure 1 and is further described in
Supplementary Results.
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LMP2B

21 (1.85)

25 (1.67)

220 (17.23)

3 (0.2)

46 (1.54)

35 (1.24)

31 (1.09)

10 (0.68)

23 (1.19)

Variant nucleotide
positionsd (percentage
of total positions)c

693

825

6600

99

1518

1155

1023

330

759

Total variant positions
compared in 33 tissuesd,e

617

727

5629

89

1305

967

877

278

553

Evaluable
nucleotide
positionsf

523 (84.8)

614 (98.0)

5099 (90.6)

42 (47.1)

959 (73.4)

851 (88.0)

764 (87.1)

241 (86.7)

379 (68.5)

Positions with no
change (% of evaluable)

54 (8.8)

57 (7.8)

97 (1.7)

b

5 (5.6)

117 (9.0)

57 (5.9)

47 (5.4)

20 (7.2)

89 (16.8)

No. of synonymous
changes (% of evaluable)

Total nucleotide positions in the coding sequence of each gene.
A position is considered “variant” if the nucleotide defined by MSS in one or more of the 33 samples analyzed differs from the reference nucleotide at that position.
c
Percentage of coding sequence nucleotide positions for which a variant from the reference sequence is shown to be present in one or more samples.
d
Total subjects’ nucleotide positions of change for each gene. For example, EBNA1, 759 equals 23 nucleotide positions of change × 33 specimens.
e
Total positions compared = # of synonymous changes + # of nonsynonymous changes + # no change + # positions without enough coverage to evaluate.
f
A nucleotide position was considered evaluable in a specific sample if it was represented in 10 or more sequencing reads.

a

EBNA3C

1493

2979

EBNA3B

LMP2A

2817

EBNA3A

1521

2835

EBNA2

1161

1464

EBNA1

EBNA‐LP

1926

Gene

LMP1

Total
nucleotide
positions in
genea

40 (6.5)

56 (7.7)

433 (7.7)

42 (47.2)

229 (17.5)

59 (6.1)

66 (7.5)

17 (6.1)

85 (15.4)

No. of nonsynonymous
changes (% of evaluable)

Changes found in nine Epstein‐Barr virus genes in 33 PTLD tissues, compared to the reference EBV‐1 genome. Bolded numbers represent genes where the percentage of
nonsynonymous changes (change in coded amino acid) was significantly higher than in other genes evaluated (see also Figure 2)

TABLE 2

DHARNIDHARKA et al.
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F I G U R E 2 Plots of adjusted percent nonsynonymous sequence changes (nonsynonymous*100/nonsynonymous + synonymous + no change)
in EBV genes, with 95% confidence intervals, as calculated by logistic regression analysis that included a random effect to adjust for repeated
measurements. Differently colored and/or patterned lines correspond to significantly different genes (Tukey adjustment)

3.5 | Comparison of EBV and anellovirus
detection methods
We confirmed that our tissue MSS results for EBV and anellovirus by quantitative tissue PCR. TTV levels by PCR
were significantly higher in samples that were positive for
anellovirus by MSS, compared to those that were negative by
MSS (P < 0.001, data not shown). Copy loads for EBV and
TTV by PCR showed a modest but significant association
with each other (Pearson correlation coefficient rho = 0.36,
P < 0.001, data not shown).

3.6
3.6.1

|

Survival analysis (patient death)

|

Contingency analyses

|

Tissue qPCR

We first analyzed for survival outcomes in relation to MSS
or qPCR results by using contingency analyses (Table S1).
Patient death within 5 years of PTLD diagnosis was associated
with anellovirus (30% dead if negative vs 57% dead if positive;
P = 0.037) and gammapapillomavirus (38% dead if negative
and 86% dead if positive; P = 0.036) positivity by MSS. Death
was not associated with EBV positivity (any method–clinical
tumor positivity, MSS or PCR positivity), WHO classification
type or early vs late onset PTLD. The only clinical parameter
to associate with higher patient death in contingency analyses
was liver location of PTLD (P = 0.031). Anellovirus tissue
MSS positivity did not associate with PTLD WHO type, any
specific location of PTLD or age at transplant.

3.6.2

We also analyzed the relationship between patient presentation or survival and levels of EBV and TTV measured by
qPCR. Neither EBV PCR copy number nor TTV PCR copy

number was associated with PTLD WHO type (data not
shown). EBV PCR copy load did not associate with patient
death (Figure 3A). In contrast, TTV PCR loads were significantly higher in patients who died (P = 0.032; Figure 3B).
The median TTV copy number was 122 in the overall cohort
and was 931 in patients who died within 5 years of PTLD
diagnosis (vs 21 in those still alive at 5 years). Patient death
occurred in 72% of those with TTV tissue load above the
median of 122, whereas patient death was only 43% for those
with TTV loads below the median (P = 0.024).

3.6.3

|

Time to event analyses

We then analyzed covariate associations to patient death
within 5 years of PTLD diagnosis using time‐to‐event analyses (Table 3). Univariable Cox regression analyses revealed
that, liver, CNS or bone marrow locations of PTLD were
significantly associated with worse patient survival. MSS
positivity for anelloviridae (HR 2.00, 95% CI 0.09, 4.70,
P = 0.09) and gammapapillomavirus (HR 2.38, 95% CI
0.87, 5.62, P = 0.06) trended toward worse patient survival.
In subset sensitivity analyses where T cell PTLD was excluded, anellovirus positivity by MSS was significantly associated with patient death within 5 years of PTLD diagnosis
(Supplementary Results).
A quantified TTV PCR load greater than the median of
122 copies/μg human DNA also trended with higher patient
death (HR 2.23, 95% CI 0.98, 5.51, P = 0.058). Notably,
the log‐transformed TTV viral load was strongly associated
with patient death (hazard ratio 1.10, 95% confidence intervals 1.02, 1.20, P = 0.016), suggesting that higher tissue
anellovirus quantity has a dose‐response relationship with
patient death.
In contrast, EBV positivity by any method, including
log‐transformed copy number, did not associate with patient
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4 variables were considered for inclusion: age at transplant,
T cell PTLD, log‐transformed EBV PCR copy number, log‐
transformed TTV PCR copy number. Only T cell type PTLD
(adjusted hazard ratio 4.14; 95% confidence intervals 1.18,
11.28, P = 0.006) and log‐transformed TTV PCR copy number (adjusted hazard ratio 1.11; 95% confidence intervals
1.02, 1.20, P = 0.012) remained independently significant.

4

F I G U R E 3 Results of EBV or TTV quantitative PCR vs
patient survival after PTLD. (A) Box and whiskers plot of EBV tissue
PCR (copies/μg human DNA), stratified by patient alive or dead at
5 years after PTLD diagnosis (P = NS). (B) Box and whisker plot
of TTV tissue PCR (copies/μg human DNA), where higher TTV
qPCR loads were present in patients dead at 5 years after PTLD
diagnosis (P = 0.032). The Y‐axis is shown on log base 10 scale.
Values below detection limit were assigned a value of 0.00001. Data
points correspond to the SAMPLES (there can be >1/subject), and
are “jittered” so that samples with overlapping markers are separated
from each other. Box‐plot characteristics: Line = Median, Top edge
of box = 75th percentile (Q3), Bottom edge of box = 25th percentile
(Q1), Upper and lower whiskers = 1.5 × IQR (Q3‐Q1)

death in time‐to‐event (Table 3) or sensitivity analyses
(Supplementary Results).

3.6.4

|

Multivariable analyses

Finally, based on our univariate associations and known literature, we fitted a multivariate Cox regression model where

|

DISCUSSION

In this study, we were able to successfully recover multiple
DNA viral genomes from stored FFPE tissue, identify viruses
in sequence data, and assess for sequence variants in key
EBV genes. A key strength of our study was the broad range
of viruses detectable, made possible by using a sequencing
approach rather than a targeted PCR‐based approach. We are
able to achieve a high degree of coverage of the EBV genome
and detected many variants, across all the nine EBV genes
tested. Certain EBV genes had higher percentages or proportions of nonsynonymous nucleotide variants.
Data on the genomic diversity of EBV and their contribution to PTLD pathogenesis or outcomes are scant, with small
sample sizes in all, given the rarity of this disease. Vaysberg
et al, from a panel of five EBV+ B cell lymphomas, identified three distinct and different variants of LMP1, with 2
gain of function mutations, which induced sustained MAP
kinase activation and c‐Fos induction.28 Notably, we detected
one of these gain of function mutations, S366T, in three of
our polymorphic PTLD samples. Using FFPE tissues, Nourse
et al found that EBV‐miRNA was profiled reliably within archival FFPE tissue in 14/23 patients, but not in tissues with
low abundance of EBV.29 In subsequent studies, the same
group found that nine CNS and 16 systemic PTLD tissues
expressed similar viral latent (EBNA2, EBNA3A, LMP1) and
lytic (BZLF1, BRLF1, BLLF1) gene mRNA transcripts.30
From studies of other EBV‐associated cancers in a nontransplant setting in a general population, the genes BRLF1,
BBRF3, and BBLF2/BBLF3 had significant associations with
gastric carcinoma.31 In Argentina, investigators detected an
association between specific BZLF1 gene variants such as
BZLF1‐A2 with lymphomas and BZLF1‐C with infectious
mononucleosis.32 Specific polymorphisms in two viral gene
promoters Cp and Qp were found in nasopharyngeal carcinoma.33 A clonal LMP1 gene containing a 30 bp deletion
(del30) was found in 46.1% of NK/T cell lymphomas and
only in 4.8% of the controls, with much worse patient survival
in those with this deletion.34 However, as shown in endemic
Burkitt lymphoma, within a geographic region, different
EBV genetic variations can coexist,35 such that specific gene
variation associations with presentation or prognosis have
been difficult. Although our study was not powered to detect
individual variants associated with survival or PTLD type,

1020
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TABLE 3
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Univariable Cox regression analysis of relationship of covariates with patient death within 5 years of PTLD diagnosis

Variable

Reference group

Hazard Ratio (95% CI)

P‐value

Age at transplant (Years)

Each 1 year age increment

1.01 (0.99, 1.03)

0.18

Male

Female

0.97 (0.45,2.17)

0.94

Heart

Bone marrow

0.33 (0.04,6.86)

0.85

Liver

Bone marrow

0.78 (0.10,15.98)

Lung

Bone marrow

0.55 (0.10,10.15)

Multi‐organ

Bone marrow

0.58 (0.05,12.71)

Kidney

Bone marrow

0.40 (0.06,7.69)

Non‐lymph node location

0.45 (0.15,1.09)

Transplant type

Locations of PTLD
Lymph node

0.10

GI tract

Non‐GI tract location

0.87 (0.34,1.97)

0.74

Liver

Non‐liver location

4.15 (1.20,11.17)

0.005

CNS

Non‐CNS location

6.74 (0.36,36.73)

0.037

Bone Marrow

Non‐bone marrow location

14.74 (2.99,61.04)

<.001

Lung

Non‐lung location

0.43 (0.07,1.47)

0.24

<1 year

0.81 (0.37,1.90)

0.61

Non‐polymorphic

0.66 (0.24,1.54)

0.36

Time from transplant to PTLD
1 year or above
PTLD type
Polymorphic
DLBCL

Non‐DLBCL

1.25 (0.58,2.76)

0.57

Classic Hodgkin

Non‐Hodgkin

0.35 (0.02,1.64)

0.28

T cell

Non‐T cell

3.58 (1.04,9.40)

0.013

Burkitt lymphoma/plasma cell

Non‐Burkitt/Plasma

0.74 (0.04,3.48)

0.76

Induction immunosuppression Regimen^ other

Anti‐thymocyte globulin

0.87 (0.29,2.87)

0.22

Unknown

Anti‐thymocyte globulin

0.55 (0.15,1.97)

Anti‐IL2 receptor

Anti‐thymocyte globulin

1.74 (0.56,5.89)

Log TTV copies/μg of Human DNA*

Each 1 log increase

1.10 (1.02,1.20)

0.016

TTV‐ copies/μg of Human DNA: >median*

TTV‐1 copies/μg of Human DNA: ≤ median

2.23 (0.98,5.51)

0.058

@

Tumor EBV status (clinical testing) Any Positive

Negative

0.55 (0.25,1.27)

0.14

Log EBV copies/μg of Human DNA*

Each 1 log increase

1.01 (0.93, 1.11)

0.76

EBV copies/μg of Human DNA: > median*

EBV copies/μg of Human DNA: ≤ median

1.28 (0.57,2.97)

0.55
0.30

MSS positive
EBV

Negative

0.67 (0.31,1.47)

Cytomegalovirus

Negative

0.52 (0.03,2.47)

0.51

HHV6 or 7

Negative

1.15 (0.52,2.49)

0.73

Simplexvirus

Negative

2.45 (0.14,11.84)

0.37

BK_polyomavirus

Negative

4.76 (0.26,24.46)

0.10

Merkel_cell_polyoma

Negative

0.52 (0.03,2.48)

0.52

Alphapapillomavirus

Negative

1.05 (0.06,4.94)

0.97

Betapapillomavirus

Negative

1.75 (0.68,4.00)

0.20

Gammapapillomavirus

Negative

2.38 (0.87,5.62)

0.06

Papillomaviridae

Negative

1.85 (0.44,5.32)

0.31

Erythroparvovirus

Negative

0.76 (0.12,2.54)

0.70

Anelloviridae

Negative

2.00 (0.91,4.70)

0.09

Number dead within 5 years = 26 and number alive at 5 years post‐PTLD = 34, except where marked separately.
^
Number dead = 25, number alive = 34, *Number dead = 24, number alive = 33, @Number dead = 25, number alive = 30.
For log‐transformed PCR values, 1 was added to all values to account for PCR copy number = 0, as log 0 is not defined and log 1 = 0.
PTLD locations were not mutually exclusive.
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we have demonstrated the technology can be successfully
be used for this approach. The significance of specific EBV
variants should be explored in future multicenter studies.
Prior studies of EBV‐negative DLBCL PTLD cases
(n = 9) have shown that human gene alterations in these cases
are more similar to those seen in immunocompetent Hodgkin
lymphoma or non‐Hodgkin lymphoma, rather than the human
gene alterations seen in EBV‐positive PTLDs (n = 24).36,37
These results suggested that viral oncogenesis is not a key
pathological pathway in EBV‐negative DLBCL PTLD. Our
results, where no DNA viral genus was overrepresented in
EBV‐negative PTLD tissue samples, would support this hypothesis, though our larger sample size of 27 EBV‐negative
PTLDs is also relatively small.
While we are not aware of any reported association between gammapapillomavirus and degree of overall immunosuppression, the association of anellovirus positivity with
patient death in our exploratory analyses was of particular
interest. The biological significance of the entire anellovirus group is unknown and evolving.38,39 Using cell‐free
DNA sequencing from plasma samples derived from thoracic organ transplant recipients, De Vlaminck et al40 found
a marked expansion of the annelloviridae family upon the
onset of immunosuppression and a lower AnV burden with
acute rejection episodes, even with appropriate drug immunosuppression levels. Blatter et al found that low AnV loads
in pediatric lung transplant recipients at 2 weeks posttransplantation were more likely to develop acute rejection within
3 months after transplant (P = 0.013).41 High Anv loads
from broncholaveolar lavage samples in lung transplant patients correlated with dysbiotic bacterial communities in the
allograft. 42 In adult kidney transplantation, low levels of
AnV associated with higher risk of late acute antibody‐mediated rejection.43 These findings suggest that anelloviruses
can be a biomarker for the overall degree of immunosuppression achieved.40
Strengths of our study include demonstrating the feasibility of MSS of old, stored FFPE tissue for detection of viral
genomes, the use of actual human PTLD specimens rather
than in vitro cell lines to investigate for EBV variants, and
the possible association with clinical presentations and outcomes. Limitations of the study include its single center and
retrospective nature. Determining which microbial gene variants are pathogenic is more challenging than with human
gene variants. In the latter, many resources are available to
help determine pathogenicity, such as well‐annotated reference genomes, published literature on mutants that are associated with clinical pathology, and prediction models. Such
tools are not as well‐developed for most microbial genome
variants. An additional limitation of the MSS technology is its
analysis of samples for short genomic reads, which may miss
larger deletions. The fragmented nature of nucleic acid from
FFPE tissue also compounds the difficulty in distinguishing
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true deletions from missing sequence coverage. For our MSS
results, we emphasized specificity over sensitivity; our strictness in calling a sample positive may have been too stringent.
EBV is the driver for PTLD onset,2,44-46 thus other agents may
act in the modulation of disease progression. Finally, patient
survival can be very different in different organ transplants
with different locations or WHO types of PTLD. We have accounted for WHO type; T cell PTLD remained independently
significant in multivariate models, consistent with other recent reports.47 Certain individual locations were associated
with higher risk of patient death in univariate analyses in our
study, but each was present in very few subjects. Individual
organ transplant type was not a significant univariate predictor in our study population. Notably, the prior PTLD‐1 trial
evaluated survival after a common treatment regimen across
different organ transplants and different WHO types. A completely homogenous PTLD study population is not possible
given the relative rarity of this disease. Immunosuppression
regimen associations were difficult to assess given the long
time period when samples were acquired and the variety of
regimens across organs.
In future, we expect to characterize further the specific types
of EBV variants (single nucleotide variants, insertions, deletions, missense mutations, etc.) in the nine EBV genes we have
analyzed so far. We will also expand our analyses to other EBV
genes, using a larger cohort for greater power. Future studies
could also involve laser capture of single malignant PTLD cells
from tissue, and single cell RNA sequencing, but our study is
the necessary first step.
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